Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Leukemia Clinical Trial

Official title:

A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00045305
• Other study ID #: CDR0000256928
• Secondary ID: E1902U10CA021115
• Status: Completed
• Phase: Phase 2
• Start date: October 24, 2006
• Est. completion date: September 2014

Study information

• Verified date: June 2023
• Source: Eastern Cooperative Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.

Description:

OBJECTIVES: - Determine the complete response rate in patients with myelodysplastic syndromes treated with reduced-intensity allogeneic bone marrow transplantation, including photopheresis, total body irradiation, and pentostatin. - Determine the disease-free and overall survival of patients treated with this regimen. - Determine the engraftment rate of donor cells in patients treated with this regimen. - Determine the extent and duration of acute and chronic graft-versus-host disease in patients treated with this regimen. - Determine the toxicity of this regimen in these patients. OUTLINE: This is a single-arm, two-stage, multicenter phase II study. - Preparative Regimen: Patients undergo photopheresis using methoxsalen on days -7 and -6 and receive pentostatin intravenously (IV )continuously on days -5 and -4. Total body irradiation is administered on days -3 and -2 for a total of 3 doses. - Transplantation: Allogeneic bone marrow or peripheral blood stem cells are infused on day 0. - Acute graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV on days -1 to 30 and then orally every 12 hours. Cyclosporine dose is then tapered beginning after day 50 and continuing for 6 months in the absence of GVHD. Once cyclosporine dose is significantly decreased, oral mycophenolate mofetil (MMF) is then administered twice a day. MMF dose is then tapered for 12 months in the absence of GVHD. Patients also receive methotrexate IV on days 1 and 3. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 33 patients would be accrued for this study within 2.1 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: September 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• One of the following cytologically proven myelodysplastic syndromes
• Refractory anemia (RA)
• RA with ringed sideroblasts
• RA with excess blasts
• Chronic myelomonocytic leukemia
• International Prognosis Scoring System (IPSS) score of at least 0.5 OR red cell transfusion dependence for at least 6 months (2 units per month)
• Patients with an IPSS score less than 0.5 may be eligible provided they previously had a higher IPSS score and received chemotherapy at that time
• Suitable human leukocyte antigen (HLA)-matched donor (related or unrelated) available
• No cord blood donors
• Related donors must be genotypically matched (HLA A, B and DR) at 5/6 or 6/6 loci and may be a sibling, parent, or child
• Unrelated donors must have high resolution typing done at A, B, C and DR, and must be matched at all or may have a single antigen or allele mismatch at no more than one of these loci
• Patients must have < 20% blasts on bone marrow study within 1 month of study entry
• Age of 18 to 70 years
• Eastern Cooperative Oncology Group performance status 0-1
• Life expectancy at least 6 months
• At least 90 days since prior autologous bone marrow transplantation
• Serum erythropoietin level greater than 100 for patients who have not received a prior course of epoetin alfa
• No iron deficiency
• Iron deficiency anemia treated with iron replacement therapy allowed
• Bilirubin less than 2.0 mg/dL
• Alkaline phosphatase less than 2 times upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times ULN
• Creatinine less than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min
• Left ventricular ejection fraction (LVEF) at least 45% by Multigated Acquisition scan (MUGA) or echocardiogram
• Carbon Monoxide Diffusing Capacity (DLCO) at least 50% of predicted (corrected for hemoglobin)
• Forced expiratory volume in 1 second (FEV_1) at least 50% of predicted
• Recovered from prior chemotherapy
• Physically and psychologically capable of undergoing study regimen
• Able to receive 600 cGy of total body irradiation
• HIV negative
• Negative pregnancy test

Exclusion Criteria:

• Pregnant or nursing
• Having other medical condition that would reduce life expectancy
• Active ongoing infection
• Prior myeloablative or nonmyeloablative allogeneic transplantation for Myelodysplastic syndrome or acute myeloid leukemia

Related Conditions & MeSH terms

• Leukemia
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasms
• Myeloproliferative Disorders
• Preleukemia
• Syndrome

Intervention

Drug:
• Cyclosporine
Immunosuppressant
• Methotrexate
Antimetabolite
• Photopheresis
Psoralens
• Mycofenolate mofetil
an antibiotic with immunosuppressamt properties isolated from Penicillium spp
• Pentostatin
Purine analogue

Procedure:
• allogeneic bone marrow
Unmanipulated allogeneic bone marrow
• peripheral blood stem cell
G-CSF mobilized peripheral blood stem cell

Radiation:
• Total body irradiation
a total of 600 cGy given in 3 200 cGy fractionated doses

Locations

Country	Name	City	State
United States	Tufts-NEMC Cancer Center	Boston	Massachusetts
United States	Jewish Hospital Cancer Center	Cincinnati	Ohio
United States	Mayo Clinic - Jacksonville	Jacksonville	Florida
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo Clinic Cancer Center	Rochester	Minnesota
United States	Mayo Clinic Scottsdale	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Eastern Cooperative Oncology Group	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate	Completed response is defined as: Bone marrow evaluation: Repeat bone marrow showing < 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia (see dysplasia qualifier under peripheral blood evaluation).; Peripheral blood evaluation [absolute values must last at least 2 months] Hemoglobin >11 g/dl (untransfused, not on erythropoietin) Neutrophils (1500/mm3 (not on a myeloid growth factor)) Platelets (100,000/mm3 (not on a thrombopoetic agent)) Blasts - 0% No dysplasia. No detectable cytogenetic abnormality, if preexisting abnormality was present	Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
Secondary	Number of Patients Who Developed Disease Progression After Achieving Complete Response	Disease free survival (DFS) was listed as a secondary endpoint in the study protocol, which would be assessed in patients who achieved complete response (CR). It was defined to be time from CR to documented progression or to death without progression. Patients without documented progression or death reported were censored at the time of last disease evaluation. However, due to the small number of patients with CR, the number of patients who developed disease progression was reported here.	Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
Secondary	Overall Survival	Overall survival (OS) is defined to be the time from registration to death from any cause, with follow-up censored at the date of last contact. Kaplan-Meier method was used to estimate the distribution of OS.	Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
Secondary	Proportion of Graft Versus Host Disease	Proportion of Graft versus Host Disease is calculated as number of patients with Graft versus Host Disease divided by all eligible and treated patients	Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.
Secondary	Time to Engraftment for Neutrophil	Time to neutrophil engraftment is defined from date of infusion to date of neutrophil engraftment. Neutrophil engraftment is defined as ANC > 500/mm3 on two consecutive measurements. The date of engraftment is the date of the first ANC > 500/mm3.	Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.
Secondary	Time to Engraftment for Platelet	Time to platelet engraftment is defined from date of infusion to date of platelet engraftment. The platelet engraftment is defined as platelets > 20,000 on two consecutive measurements, at least seven days apart, without platelet transfusions in between and for at least three days before the first measurement that is over 20,000. The date of engraftment is the date of the first measurement that is over 20,000.	Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.